Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more
Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

The clinical implications of thrombocytopenia in adults with severe falciparum malaria: a retrospective analysis

  • Josh Hanson1, 2Email author,
  • Nguyen Hoan Phu3,
  • Mahtab Uddin Hasan4,
  • Prakaykaew Charunwatthana1,
  • Katherine Plewes1,
  • Richard J Maude1, 5,
  • Panote Prapansilp1, 6,
  • Hugh WF Kingston1,
  • Saroj K Mishra4,
  • Sanjib Mohanty4,
  • Ric N Price2, 5,
  • M Abul Faiz1, 7,
  • Arjen M Dondorp1, 5,
  • Nicholas J White1, 5,
  • Tran Tinh Hien3 and
  • Nicholas PJ Day1, 5
BMC Medicine201513:97

https://doi.org/10.1186/s12916-015-0324-5

Received: 4 December 2014

Accepted: 13 March 2015

Published: 24 April 2015

Abstract

Background

Thrombocytopenia is a common finding in adults with severe falciparum malaria, but its clinical and prognostic utility is incompletely defined.

Methods

Clinical and laboratory data from 647 adults with severe falciparum malaria were analysed retrospectively to determine the relationship between a patient’s platelet count on admission to hospital and their subsequent clinical course.

Results

On admission, 614 patients (94.9%) were thrombocytopenic (platelet count <150 × 109/L) and 328 (50.7%) had a platelet count <50 × 109/L. The admission platelet count was inversely correlated with parasite biomass (estimated from plasma PfHRP2 concentrations, rs = −0.28, P = 0.003), the degree of microvascular sequestration (measured with orthogonal polarizing spectral imaging, rs = −0.31, P = 0.001) and disease severity (the number of World Health Organization severity criteria satisfied by the patient, rs = −0.21, P <0.001). Platelet counts were lower on admission in the patients who died (median: 30 (interquartile range 22 to 52) × 109/L versus 50 (34 to 78) × 109/L in survivors; P <0.001), but did not predict outcome independently from other established laboratory and clinical prognostic indices. The 39 patients (6%) with profound thrombocytopenia (platelet count <20 × 109/L) were more likely to die (odds ratio: 5.00, 95% confidence interval: 2.56 to 9.75) than patients with higher platelet counts, but these high-risk patients could be identified more rapidly with simple bedside clinical assessment. The admission platelet count did not reliably identify the 50 patients (7.7%) with major bleeding during the study.

Conclusions

Thrombocytopenia is a marker of disease severity in adults with falciparum malaria, but has limited utility in prognostication, triage and management.

Keywords

BleedingPatient triageSevere falciparum malariaThrombocytopenia

Background

Thrombocytopenia is an early and consistent feature of malaria [1-4], but its pathogenesis remains incompletely understood. In falciparum malaria there is increased platelet consumption as evidenced by shortened survival of radiolabelled platelets [5] and the finding of plentiful megakaryocytes in patients’ bone marrow [6] and appropriately elevated plasma thrombopoietin levels [7]. Both systemic microvascular sequestration [8] and endothelial activation [9,10] may play a pathophysiological role, a hypothesis supported by the observation that the radiolabelled platelets of patients with falciparum malaria are diffusely sequestered, rather than pooling in the liver or spleen [5]. Yet while thrombocytopenia is a ubiquitous laboratory finding, it had been thought to have limited clinical significance, as major bleeding is relatively uncommon in the disease [11].

Recently it has been suggested that thrombocytopenia may have important implications for patient triage. Population studies have shown an association between thrombocytopenia and outcome [12] and a recent study from India proposed that thrombocytopenia should be added to the World Health Organization (WHO) criteria for the definition of severe malaria [13]. To clarify this issue, data from adults with severe falciparum malaria prospectively enrolled in clinical studies of severe malaria were analysed to determine if the platelet count could assist in clinical decision-making and whether the degree of thrombocytopenia has predictive utility independent of current clinical and laboratory prognostic indices. Measures of microvascular sequestration and endothelial activation and their relationship with the platelet count were examined to further explore the pathogenesis of the thrombocytopaenia seen in the disease.

Methods

Two datasets were combined for this analysis. The first (n = 560) was compiled prospectively at the Centre for Tropical Diseases in Ho Chi Minh City, Vietnam, between 1991 and 1996 in a study that compared the efficacy of artemether and quinine in adults with severe falciparum malaria [14]. The second comprised data collected prospectively in studies assessing a range of adjunctive therapies in severe falciparum malaria at Chittagong Medical College Hospital, Bangladesh, and Ispat General Hospital, Rourkela, India, between 2004 and 2011 [15-18].

Malaria transmission was low and seasonal at all sites. Falciparum malaria was diagnosed if a blood film showed asexual forms of Plasmodium falciparum. When expert microscopy was not available immediately, patients were enrolled if an immunochromatographic rapid diagnostic test (Paracheck Pf, Orchid Biomedical Systems, Goa, India) was positive; P. falciparum infection was confirmed later by microscopy of a simultaneously collected blood slide.

All patients satisfied a strict definition of severe falciparum malaria that used modified WHO criteria [19], including cerebral malaria (Glasgow Coma Scale (GCS) <11); severe anaemia (haematocrit <20% with a parasite count > l00,000/mm3); renal failure (blood urea nitrogen ≥21.4 mmol/L or plasma creatinine level ≥265 μmol/L); pulmonary oedema (oxygen saturation <90% and bibasal crepitations); generalized convulsions; acidosis (venous bicarbonate <15 mmol/L); hyperparasitaemia (peripheral parasitaemia >10%); hyperlactataemia (venous lactate >4 mmol/L); jaundice (bilirubin >43 μmol/L and a parasite count > l00,000/mm3); hypoglycaemia (glucose <2.2 mmol/L); and spontaneous bleeding or shock (systolic blood pressure <80 mmHg with cool extremities). Patients were excluded if they were <14 years of age or if they had received parenteral anti-malarial treatment for >48 hours before enrolment. Disease severity was defined by the number of these criteria that a patient satisfied. The independent prognostic utility of the admission platelet count was compared with the widely validated RCAM score [20-22] calculated from the patients’ respiratory rate and GCS on admission (Table 1). Major bleeding was defined as bleeding which resulted in death or necessitated blood transfusion.
Table 1

Calculation of the RCAM score

 

Score

Variable

0 (Normal)

1 (Abnormal)

2 (Very abnormal)

Glasgow coma scale

15

11 to 14

≤10

Respiratory rate

<20

20 to 39

≥40

RCAM (0 to 4) is calculated as the respiratory rate score (0 to 2) plus the GCS score (0 to 2).

On enrolment, a history was taken, a physical examination performed and venous blood collected. In Vietnam, patients were randomized to receive intramuscular quinine (n = 271) or intramuscular artemether (n = 279); all the Bangladeshi and Indian patients received intravenous artesunate. Patients received supportive care as per contemporary WHO treatment guidelines [11,23,24]. Access to mechanical ventilation was limited in Vietnam; access to both mechanical ventilation and renal replacement therapy was limited in Bangladesh. Platelet transfusion was not available at any of the sites. The peripheral parasite count (parasites/μL) on admission was calculated from the thin film using the formula: parasite count/1,000 red blood cells × 125.6 × haematocrit (%); or from the thick film using the formula: parasite count/200 white blood cells × 40. In Vietnam haematological indices were manually determined in the hospital laboratory; in Bangladesh and India they were measured with an automated analyser in local private laboratories.

In Vietnam the hospital laboratory performed most biochemical analysis, but plasma glucose and lactate were measured on the ward using dedicated online analysers (Analox, Middlesborough, United Kingdom). Biochemical indices were measured in Bangladesh and India using portable handheld analysers (i-Stat, Abbott, Princeton, New Jersey, USA). Plasma was processed and stored at −80°C for analysis of other laboratory parameters: plasma Plasmodium falciparum histidine rich protein 2 (PfHRP2), a measure of parasite biomass, was measured in Bangkok, Thailand, using ELISA (Cellabs, Sydney, New South Wales, Australia), according to the manufacturer’s instructions with minor modifications [25]; angiopoietin-2 (Ang-2), a measure of endothelial activation, was measured in Darwin, Australia, using ELISA (R&D Systems, Minneapolis, Minnesota, USA) [26].

In the Bangladeshi and Indian patients video recordings of blood flow in the microcirculation were collected with an orthogonal polarizing spectral (OPS) imaging device (either Cytoscan from Cytometrics, Heathpark Honiton, Devon, United Kingdom or Microscan from Microvision Medical, Amsterdam, the Netherlands) and quantified using image analysis software (Open Lab 3.1.5, Improvision, Waltham, Massachusetts, USA) as described previously [17].

Statistics

Data were analysed using statistical software (Stata version 10, StataCorp, College Station, Texas, USA). Correlation coefficients were determined using Spearman’s method. Groups were analysed using the Kruskal-Wallis test and the chi-squared test. Logistic regression was performed where necessary and to control for any influence of the study site or the administered anti-malarial therapy.

Ethics review

All of the studies received prospective ethical approval from OXTREC (Oxford Tropical Research Ethics Committee) and local ethics review bodies. The ethics and scientific-review committee of The Center for Tropical Diseases in Ho Chi Minh City approved the Vietnamese study, the Bangladeshi Medical Research Council approved the Bangladeshi studies and the institutional ethical board of Ispat General Hospital approved the Indian studies.

Results

Patients

Of the 560 Vietnamese patients, 538 (96.1%) had a platelet count documented on admission. The 22 patients who did not have a platelet count recorded had neither more severe disease (P = 0.4), nor were more likely to die (P = 0.12). Of the 142 Bangladeshi and Indian patients, 109 (76.8%) had an admission platelet count recorded; 31 of the 33 patients with a missing value were studied in 2004 and 2005 when platelet counts were not routinely collected for the studies. The two remaining Bangladeshi and Indian patients without a documented platelet count (from 2011 and 2008 respectively) both survived.

The baseline characteristics of the 647 patients with a platelet count recorded on admission are presented in Table 2. Overall, 107 patients (16.5%) died before discharge; the case-fatality rate was higher in the Bangladeshi and Indian patients than the Vietnamese patients (30 out of 109 (27.5%) versus 77 out of 538 (14.3%); odds ratio (OR) (95% confidence interval (CI)): 2.27 (1.40 to 3.69), P = 0.001), although the difference was not significant when controlled for disease severity (OR (95% CI): 1.46 (0.84 to 2.52), P = 0.18).
Table 2

Baseline characteristics of the patients

Variable

n

All (n = 647)

Survived (n = 540)

Died (n = 107)

P

Age (years)

646

30 (22 to 42)

30 (22 to 40)

34 (26 to 45)

0.003

Sex (% male)

646

483 (75%)

409 (76%)

74 (69%)

0.14

Temperature (°C)

647

38.3 (37.5 to 39.0)

38.3 (37.5 to 39.0)

38 (37 to 39.0)

0.04

Mean arterial pressure (mmHg)

646

76.7 (70 to 86.7)

76.7 (70 to 86.7)

79.2 (66.9 to 90.0)

0.31

Heart rate (beats/minute)

641

106 (96 to 120)

105 (95 to 120)

113 (100 to 123)

0.01

Respiratory rate (breaths/minute)

642

28 (24 to 32)

28 (24 to 32)

32 (28 to 40)

<0.001

Glasgow coma scale score

647

10 (8 to 15)

10 (8 to 15)

9 (7 to 13)

<0.001

Haematocrit (%)

646

30 (24 to 36)

30 (24 to 36)

30 (23 to 36)

0.95

Reticulocyte count (%)

514

0.8 (0.4 to 1.2)

0.8 (0.4 to 1.2)

0.5 (0.3 to 1.1)

0.008

Reticulocyte index

517

0.5 (0.3 to 0.8)

0.5 (0.3 to 0.9)

0.4 (0.2 to 0.7)

0.01

White cell count (× 109/L)

643

8.7 (6.2 to 12)

8.1 (6 to 11.2)

11.8 (9.1 to 16.3)

<0.001

Platelet count (× 109/L)

647

48 (30 to 72)

50 (34 to 78)

30 (22 to 52)

<0.001

Mean platelet volume (fL)

34

11.4 (10.4 to 12.4)

11.5 (10.4 to 12.4)

11.3 (11.2 to 12.6)

0.82

Parasite count (parasites/mL)

639

90.4 (18.5 to 327.6)

78.6 (16.1 to 326.7)

101.8 (33.3 to 373.3)

0.09

Sequestration (% blocked capillaries)

107

13.3 (3.3 to 31.5)

10 (2.9 to 26.6)

23.2 (10.0 to 44.0)

0.008

PfHRP2 (ng/mL)

109

2,351 (1,198 to 4,805)

2,187 (976 to 4,216)

3,275 (1,479 to 6,406)

0.07

Lactate (mmol/L)

640

3.5 (2.0 to 4.6)

3.2 (2.0 to 4.6)

5.7 (3.4 to 9.0)

<0.001

Base deficit (mEq/L)

395

5 (2 to 10)

5 (2 to 8)

11 (7 to 17)

<0.001

Anuric on admission

565

51/565 (9%)

35/483 (7.3%)

16/82 (19.5%)

<0.001

Shock on admission

647

47/647 (7.3%)

27/540 (5%)

20/107 (18.7%)

<0.001

Pulmonary oedema on admission

646

15/646 (2.3%)

8/539 (1.5%)

7/107 (6.5%)

0.002

Bleeding on admission

646

34/646 (5.2%)

26/539 (4.8%)

8/107 (7.5%)

0.26

Sodium (mmol/L)

460

133 (127 to 138)

133 (127 to 138)

135 (130 to 140)

0.02

Potassium (mmol/L)

525

4.0 (3.6 to 4.5)

4.0 (3.5 to 4.5)

4.2 (3.7 to 4.8)

0.02

Creatinine (μmol/L)

644

176 (123 to 282)

176 (123 to 254)

239 (146 to 441)

<0.001

Total bilirubin (μmol/L)

544

57.8 (30.6 to 146.2)

51 (27.2 to 119.0)

146.2 (52.7 to 248.2)

<0.001

Direct bilirubin (μmol/L)

420

27.2 (13.6 to 71.4)

23.8 (13.6 to 64.6)

62.9 (20.4 to 127.6)

<0.001

Indirect bilirubin (μmol/L)

420

34.8 (17.0 to 74.8)

34 (14.4 to 64.6)

73.1 (40.4 to 102.3)

<0.001

Angiopoietin-2 (ng/mL)

152

18.2 (10.2 to 29.8)

13.5 (9.4 to 25.1)

25 (14.8 to 41.0)

<0.001

The values represent the median (interquartile range) and absolute number (%). PfHRP2: Plasmodium falciparum histidine rich protein 2.

Most patients (614 out of 647, 94.9%) were thrombocytopenic (platelet count <150 × 109/L) on admission; 328 (50.7%) had a platelet count <50 × 109/L (Figure 1). The mean platelet volume was only available in 34 patients but was generally increased: median (IQR) 11.4 (10.4 to 12.4) fL (normal range 7.2 to 11.7 fL).
Figure 1

The peripheral platelet count of the patients on admission to hospital.

Association with bleeding complications

Bleeding was present on admission in 20 out of 328 patients (6.1%) with a platelet count of <50 × 109/L and 14 out of 319 patients (4.4%) with a count ≥50 × 109/L (P = 0.33). Bleeding developed in a further 60 out of 328 patients (18.3%) with an admission platelet count of <50 × 109/L and 37 out of 319 patients (11.6%) with a count ≥50 × 109/L (P = 0.02). Major bleeding was not common, occurring at some point in the admission of 50 (7.7%) of the patients (30 deaths, 20 additional patients requiring blood transfusion). Although the admission platelet count was lower in patients with major bleeding (median (IQR, range): 40 (28 to 60, 9 to 420) × 109/L) than in patients without major bleeding (50 (30 to 75, 4 to 290) × 109/L; P = 0.02), it failed to identify either population reliably (Table 3). Patients dying with bleeding complications rarely died from bleeding alone; these patients also usually had multi-organ dysfunction and satisfied a median (IQR) of 3 (2 to 4) other WHO severity criteria on admission. Similarly the patients with bleeding that required blood transfusion were also frequently anaemic on enrolment (median (IQR) haematocrit 26% (23 to 32%)); many would have required blood transfusion even if bleeding had not supervened. Major bleeding episodes were most commonly gastrointestinal in origin. Proton pump inhibitor therapy was not available at the time of the Vietnam study and acid suppression therapy was administered rarely prior to hospitalisation at any of the study sites.
Table 3

Association between the admission platelet count, bleeding complications and outcome

Platelet count on admission (× 10 9 /L)

n

Any bleeding during hospitalisation

Died with bleeding complications

Survived but required blood transfusion for bleeding

Major bleeding a

Died from any cause

Less than 20

39

6 (15%)

0

3 (7.7%)

3 (7.7%)

18 (46%)

20 to 49

289

74 (26%)

20 (6.9%)

9 (3.1%)

29 (10 %)

59 (20%)

50 to 99

235

46 (20%)

9 (3.8%)

6 (2.6%)

15 (6.4%)

24 (10%)

≥100

84

5 (6%)

1 (1.2%)

2 (2.4%)

3 (3.6%)

6 (7.1%)

Total

647

131(20%)

30 (4.6%)

20 (3.1%)

50 (7.7%)

107 (17%)

a Patients who died from bleeding complications or who had bleeding and received blood transfusion.

Association with disease severity, parasite burden and measures of endothelial function

The admission platelet count correlated inversely with disease severity (rs = −0.21, P <0.001) and the circulating parasite count (rs = −0.29, P <0.001). Measures of sequestration (OPS imaging data) and total parasite biomass (PfHRP2) were only available in Bangladeshi and Indian patients; however, both correlated inversely with the admission peripheral platelet count (rs = −0.31, P = 0.001 and rs = −0.28, P = 0.003, respectively). Admission plasma Ang-2 concentrations were available in 152 cases (92 Bangladeshi and 60 Vietnamese patients) and were markedly elevated (median (IQR) 18.2 (10.3 to 29.8) ng/mL). However, an inverse correlation between plasma Ang-2 concentrations and the peripheral platelet count failed to reach statistical significance (rs = −0.15, P = 0.059) (Table 4).
Table 4

Association between the platelet count and clinical and other laboratory indices on admission

Variable

Platelets ≥ 50 × 10 9 /L n = 319

Platelets <50 × 10 9 /L n = 328

P

Died

30/319 (9.4%)

77/328 (23.5%)

<0.001

Age (years)

28 (22 to 38)

33 (24 to 45)

<0.001

Sex (% male)

237/319 (74.0%)

246/327 (75.2%)

0.79

Temperature (°C)

38.5 (37.5 to 39.0)

38.1 (37.5 to 39.2)

0.74

Mean arterial pressure (mmHg)

76.7 (70.0 to 86.7)

78.3 (70.0 to 90.0)

0.05

Heart rate (beats/minute)

100 (96 to 120)

110 (95 to 120)

0.09

Respiratory rate (breaths/minute)

28 (24 to 32)

28 (24 to 36)

0.006

Glasgow Coma Scale Score

10 (8 to 15)

11 (8 to 15)

0.11

Haematocrit (%)

28 (23 to 35)

31 (25 to 38)

<0.001

White cell count (× 109/L)

8.8 (6.3 to 11.6)

8.6 (6.1 to 12.6)

0.75

Reticulocyte count (%)

0.9 (0.5 to 1.5)

0.6 (0.3 to 1.0)

<0.001

Parasite count (parasites/mL)

42.2 (10.4 to 184.3)

151.6 (32.3 to 479.9)

<0.001

Sequestration (% blocked capillaries)

6.6 (1.7 to 18.3)

16.6 (6.6 to 34.9)

0.01

PfHRP2 (ng/mL)

1,739 (783 to 3,203)

2,834 (1,482 to 5,209)

0.01

Lactate (mmol/L)

2.9 (1.9 to 4.4)

4.0 (2.4 to 6.3)

<0.001

Base deficit (mEq/L)

4 (1 to 8)

6 (3 to 11)

<0.001

Creatinine (μmol/L)

164 (115 to 264)

185 (138 to 310)

0.007

Total bilirubin (μmol/L)

44.2 (23.8 to 115.6)

74.8 (40.8 to 170.0)

<0.001

Indirect bilirubin (μmol/L)

26.5 (13.6 to 54.4)

47.6 (23.8 to 85.0)

<0.001

Angiopoietin-2 (ng/mL)

16.3 (9.4 to 30.2)

19.4 (11.6 to 29.8)

0.14

Anuric on admission

20/289 (6.9%)

31/276 (11.2%)

0.07

Shock on admission

19/319 (6.0%)

28/328 (8.5%)

0.21

Pulmonary oedema on admission

6/319 (1.9%)

9/327 (2.8%)

0.46

The values represented the median (interquartile range) and absolute number (%). PfHRP2: Plasmodium falciparum histidine rich protein 2.

Association with outcome and independent prognostic utility

The admission platelet count correlated with the risk of death in both datasets. Overall, the median (IQR) platelet count in the patients who died was 30 (22 to 52) × 109/L compared to 50 (34 to 78) × 109/L in survivors (P = 0.0001) (Figure 2). The case-fatality rate increased with declining platelet count (Table 3): 77 out of 328 patients (23%) with severe thrombocytopenia (<50 × 109/L) died (OR (95% CI): 2.96 (1.88 to 4.66), although when considered with other laboratory indices of disease severity, severe thrombocytopenia was not independently predictive of outcome (Table 5). Of the 39 patients with profound thrombocytopenia (<20 × 109/L), 18 (46%) died (OR: 5.00 (95% CI 2.56 to 9.75). However, these patients were usually relatively easy to identify: the median (IQR) GCS of these 39 patients was 8 (6 to 12) and the median (IQR) respiratory rate was 33 (26 to 44) breaths per minute. The 18 patients with profound thrombocytopenia on admission who later died concurrently satisfied a median (IQR) of 3 (3 to 4) WHO severity criteria and had pronounced derangement of other laboratory indices (median (IQR) plasma lactate, 6 (3.6 to 9.3) mmol/L; base deficit, 12 (9 to 17) mEq/L; plasma creatinine, 229 (140 to 453) μmol/L; and total bilirubin, 195 (105 to 260) μmol/L).
Figure 2

The relationship between the platelet count on admission and outcome.

Table 5

Independent ability of laboratory variables measured on admission to predict outcome

Variable

Cut-off

Number a

Odds ratio

95% Confidence interval

P

White cell count

>11 × 109/L

195 (30%)

2.74

1.53 to 4.89

0.001

Plasma creatinine

>265 μmol/L

176 (27%)

2.40

1.3 to 4.43

0.005

Plasma lactate

>4 mmol/L

260 (41%)

2.25

1.26 to 4.02

0.006

Total bilirubin

>51 μmol/L

313 (57%)

2.26

1.13 to 4.50

0.02

Platelet count

<50 × 109/L

328 (51%)

1.75

0.96 to 3.18

0.07

Reticulocyte count

<0.5%

190 (37%)

1.19

0.63 to 2.26

0.59

aNumber (%) of patients with a value meeting the cut-off. The denominator for the calculation of the percentage was the number of patients in the dataset with a measurement available (not all patients had data for every variable). Multivariable logistic regression with death as the dependent variable; explanatory variables chosen on the basis of a significant association with outcome in univariate analysis (with P <0.01 allowing for multiple comparisons, see Table 2). The cut-offs were chosen based on the WHO severity criteria cut-off (for those that are WHO severity criteria: creatinine, lactate and bilirubin). For those that are not WHO severity criteria, the cut-offs were based on the reference range (white blood cell count and reticulocyte count) and previous studies (platelet count). Base deficit was not included in the model as there were fewer data for this variable; acidosis was represented by plasma lactate.

In total, 642 patients (99.2%) had data allowing retrospective calculation of a RCAM score on admission; 104 of these patients died, 93 (89.4%) of whom had a RCAM score ≥2. The platelet count did not improve the identification of the 11 patients who died but were classified as low-risk by the RCAM score (RCAM score <2). The platelet counts of these 11 patients (median (IQR, range): 40 (30 to 60, 24 to 98) × 109/L)) were not statistically or clinically significantly different to the 151 patients with an RCAM score <2 who survived: 48 (32 to 78, 8 to 272) × 109/L) (P = 0.56) (Figure 3). Of the patients with profound thrombocytopenia (<20 × 109/L), 34 out of 39 (87.2%) had a RCAM score ≥2; the five patients with profound thrombocytopenia but a RCAM score <2 all survived.
Figure 3

Ability of the platelet count on admission to predict outcome when compared the simple RCAM score.*In five patients the respiratory rate on admission was not recorded. IQR, interquartile range.

Discussion

In this multi-centre study of adults with severe falciparum malaria, the platelet count on admission correlated with disease severity and outcome, but had limited independent prognostic utility when considered with other laboratory indices. Knowledge of the platelet count offered no significant prognostic advantage over determination of the respiratory rate and GCS. The platelet count on admission was lower in patients who went on to develop major bleeding, but was unable to identify this population reliably.

Thrombocytopenia was more frequent in this series than in previous studies of adults with falciparum malaria [2,3,27], presumably as a result of a strict case definition leading to the enrolment of patients with more severe disease. The increased mean platelet volume, although available in few patients, suggests the presence of young, functional platelets, and likely explains the relatively low incidence of major bleeding - despite the profound thrombocytopenia - seen in the study. This low incidence of major bleeding and the significant challenges associated with the delivery of blood products in the resource-poor setting [28] argues strongly against the routine use of platelet transfusions in these patients. The prompt and spontaneous recovery seen in the platelet counts of this patient population provides additional support for this clinical approach [29].

After an association between thrombocytopenia and outcome was demonstrated in a large Indonesian population-based study of malaria, it was suggested that a platelet count of less than 20 × 109/L should be used as a severity criterion in malaria and that the platelet count might have use in patient triage [12]. An Indian hospital-based study reached similar conclusions [13]. A platelet count has the virtue of being easier to measure than some other recognized laboratory predictors of mortality, such as plasma lactate and base deficit. Our series confirms that profound thrombocytopenia should alert clinicians managing patients with malaria - patients with a platelet count below 20 × 109/L were five times more likely to die than patients with a higher platelet count. However, if clinicians in this series had used the platelet count to triage patients, it would not have resulted in significant changes in their management. None of the patients who would later die despite being classified as low-risk with the simple bedside RCAM score had an admission platelet count below 20 × 109/L. Thus, whilst there is an association between the presence of profound thrombocytopenia and the likelihood of a complicated course, the addition of another severity criterion to the already complex definition of severe falciparum malaria [30] may not assist clinicians substantially.

OPS imaging has been used to demonstrate microvascular obstruction in vivo in adults with falciparum malaria [15]. The correlation seen in this series between microvascular obstruction and the circulating platelet count may represent the diffuse sequestration of radiolabelled platelets seen in thrombocytopenic patients with falciparum malaria [5]. Certainly platelets have been implicated in the pathogenesis of two of the processes (auto-agglutination [31] and cytoadherence [32]) that contribute to microvascular obstruction, and increased numbers of platelets and platelet-fibrin thrombi have been reported in the cerebral microcirculation of paediatric cases of fatal falciparum malaria [8]. However, platelets are notable by their absence from the microcirculation in adult post-mortem series [33,34]. Furthermore thrombocytopenia is also frequent in Plasmodium vivax malaria [12,27], a disease in which significant sequestration is absent [35]. Although severe thrombocytopenia is less frequent in vivax malaria, there are many shared findings, including increased mean platelet volumes and a correlation with the circulating parasite count [36], suggesting that there are common pathways in the pathogenesis of the thrombocytopenia in the two infections.

One of these common pathways is likely to be endothelial activation [34,37]. During endothelial activation, activated high-multimeric von Willebrand Factor (vWF) is released from specialized secretory vesicles in endothelial cells known as Weibel-Palade bodies (WPBs) [38]. Once in the circulation, vWF aggregates platelets, resulting in their clearance from the circulation. Studies performed in both falciparum and vivax malaria demonstrate an inverse association between the circulating platelet count and plasma concentrations and activity of vWF [9,10]. Falls in the plasma concentrations of ADAMTS13, a regulating enzyme that catabolizes vWF multimers, are also seen in infections with both species [9,10]. Although vWF and ADAMTS13 were not determined in this series, plasma concentrations of Ang-2 were markedly elevated, suggesting the presence of pronounced systemic endothelial activation. Indeed, Ang-2 is stored in WPBs and is released with vWF during WPB exocytosis.

An interaction between microvascular obstruction and endothelial activation may explain the association between the OPS findings and the circulating platelet count seen in this series [34]. The resting, un-activated endothelium constitutively releases nitric oxide, which helps maintain endothelial quiescence and also directly inhibits platelet aggregation [39,40]. The shear stress of normally flowing blood is the principal signal for this nitric oxide release [40] and it would therefore be expected that microvascular obstruction could lead to endothelial activation via this mechanism. Microvascular obstruction also leads to tissue hypoperfusion and hypoxia - another potent stimulus for endothelial activation. Endothelial activation facilitates further cytoadherence through the upregulation of endothelial receptors that act as ligands for parasitized erythrocytes [34], resulting in further microvascular obstruction and potentially precipitating a vicious cycle.

The study has other noteworthy haematological findings. Erythropoiesis was significantly depressed with a reticulocyte production index of less than 1 in almost 90% of the patients. Accordingly, most patients were anaemic but severe anaemia (haematocrit <20%) was relatively infrequent, a finding that may reflect the fact that this study was performed exclusively in adults [41]. It suggests that prognostic tools that use the platelet count and haemoglobin concentration may have limited utility in the adult population [12]. The median white blood cell count was greater in this cohort than in outpatients with malaria in whom mild leucopenia is typical [42]. The admission white cell count was significantly higher in the patients who died than in survivors, an association that has been recognized previously [13,43].

Our study had significant limitations. Its retrospective design precluded complete data collection. Measurements of vWF and ADAMTS13 concentrations and activity would have defined the extent of this pathway’s contribution to the pathogenesis of thrombocytopenia. Coagulation studies would have defined the contribution of coagulopathy to bleeding complications, although disseminated intravascular coagulation was rarely suspected clinically. The study assessed the prognostic utility of the admission platelet count, but sequential measurement may have improved its ability to predict bleeding complications, in particular. The dataset consisted of patients who had already satisfied a definition of severe malaria; the prognostic utility of the platelet count may be different outside of a study setting. Because the studies only enrolled adults, the findings cannot necessarily be generalized to children.

Conclusions

Adults with severe falciparum malaria are usually thrombocytopenic, some profoundly so. Despite this, the risk of major bleeding is relatively low. Patients with multi-organ involvement and those who will die before discharge are more likely to have a lower platelet count; however, these patients are more reliably identified by simple clinical assessment and traditional laboratory indices of severe disease.

Declarations

Acknowledgements

We thank the directors and staff of the trial hospitals and the doctors, research nurses and research assistants for their help; in particular Dr Sophia Lam, Dr Sam Douthwaite and Dr Sophie Cohen, who collected and collated data in Bangladesh and India. We also thank Dr Gareth Turner (MORU) and Professor Nick Anstey for valuable and constructive advice during the preparation of the manuscript and Dr Kamolrat Silamut, Dr Kesinee Chotinavich, Dr Charlie Woodrow (all MORU) and Kim Piera (Menzies), who provided valuable laboratory support. JH is supported by the National Health and Medical Research Council of Australia. RNP is supported by the Wellcome Trust. NJW, NPJD and AMD are supported by the Wellcome Trust as part of the Wellcome Trust-Mahidol University-Oxford Tropical Medicine Research Programme.

Funding

This work was supported by the Wellcome Trust of Great Britain and the National Health and Medical Research Council of Australia. Neither funding body played any role in the collection, analysis and interpretation of data; in the writing of the manuscript; or in the decision to submit the review for publication.

Authors’ Affiliations

(1)
Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University
(2)
Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University
(3)
Oxford University Clinical Research Unit, Hospital for Tropical Diseases
(4)
Chittagong Medical College
(5)
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford
(6)
Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University
(7)
Dev Care Foundation

References

  1. Patel U, Gandhi G, Friedman S, Niranjan S. Thrombocytopenia in malaria. J Natl Med Assoc. 2004;96:1212–4.PubMedPubMed CentralGoogle Scholar
  2. Scott CS, Van Zyl D, Ho E, Ruivo L, Mendelow B, Coetzer TL. Thrombocytopenia in patients with malaria: automated analysis of optical platelet counts and platelet clumps with the Cell Dyn CD4000 analyser. Clin Lab Haematol. 2002;24:295–302.View ArticlePubMedGoogle Scholar
  3. Jadhav UM, Patkar VS, Kadam NN. Thrombocytopenia in malaria–correlation with type and severity of malaria. J Assoc Physicians India. 2004;52:615–8.PubMedGoogle Scholar
  4. de Mast Q, de Groot PG, van Heerde WL, Roestenberg M, van Velzen JF, Verbruggen B, et al. Thrombocytopenia in early malaria is associated with GP1b shedding in absence of systemic platelet activation and consumptive coagulopathy. Br J Haematol. 2010;151:495–503.View ArticlePubMedGoogle Scholar
  5. Karanikas G, Zedwitz-Liebenstein K, Eidherr H, Schuetz M, Sauerman R, Dudczak R, et al. Platelet kinetics and scintigraphic imaging in thrombocytopenic malaria patients. Thromb Haemost. 2004;91:553–7.PubMedGoogle Scholar
  6. Essien EM. The circulating platelet in acute malaria infection. Br J Haematol. 1989;72:589–90.View ArticlePubMedGoogle Scholar
  7. Kreil A, Wenisch C, Brittenham G, Looareesuwan S, Peck-Radosavljevic M. Thrombopoietin in Plasmodium falciparum malaria. Br J Haematol. 2000;109:534–6.View ArticlePubMedGoogle Scholar
  8. Grau GE, Mackenzie CD, Carr RA, Redard M, Pizzolato G, Allasia C, et al. Platelet accumulation in brain microvessels in fatal pediatric cerebral malaria. J Infect Dis. 2003;187:461–6.View ArticlePubMedGoogle Scholar
  9. de Mast Q, Groot E, Asih PB, Syafruddin D, Oosting M, Sebastian S, et al. ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria. Am J Trop Med Hyg. 2009;80:492–8.PubMedGoogle Scholar
  10. Lowenberg EC, Charunwatthana P, Cohen S, van den Born BJ, Meijers JC, Yunus EB, et al. Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease, ADAMTS13. Thromb Haemost. 2010;103:181–7.View ArticlePubMedGoogle Scholar
  11. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg. 2000;94:S1–90.Google Scholar
  12. Lampah DA, Yeo TW, Malloy M, Kenangalem E, Douglas NM, Ronaldo D, et al. Severe malarial thrombocytopenia: a risk factor for mortality in Papua. Indonesia J Infect Dis. 2014;211:623–34.View ArticlePubMedGoogle Scholar
  13. Saravu K, Rishikesh K, Kamath A. Determinants of mortality, intensive care requirement and prolonged hospitalization in malaria - a tertiary care hospital based cohort study from South-Western India. Malar J. 2014;13:370.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Tran TH, Day NP, Nguyen HP, Nguyen TH, Pham PL, Dinh XS, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med. 1996;335:76–83.View ArticlePubMedGoogle Scholar
  15. Dondorp AM, Ince C, Charunwatthana P, Hanson J, van Kuijen A, Faiz MA, et al. Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria. J Infect Dis. 2008;197:79–84.View ArticlePubMedGoogle Scholar
  16. Maude RJ, Silamut K, Plewes K, Charunwatthana P, Ho M, Abul Faiz M, et al. Randomized controlled trial of levamisole hydrochloride as adjunctive therapy in severe falciparum malaria with high parasitemia. J Infect Dis. 2013;209:120–9.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Hanson J, Lam SW, Mahanta KC, Pattnaik R, Alam S, Mohanty S, et al. Relative contributions of macrovascular and microvascular dysfunction to disease severity in falciparum malaria. J Infect Dis. 2012;206:571–9.View ArticlePubMedGoogle Scholar
  18. Maude RJ, Hoque G, Hasan MU, Sayeed A, Akter S, Samad R, et al. Timing of enteral feeding in cerebral malaria in resource-poor settings: a randomized trial. PLoS One. 2011;6:e27273.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Severe and complicated malaria. World Health Organization, Division of Control of Tropical Diseases. Trans R Soc Trop Med Hyg. 1990;84:1–65.Google Scholar
  20. Hanson J, Lee SJ, Mohanty S, Faiz MA, Anstey NM, Price RN, et al. Rapid clinical assessment to facilitate the triage of adults with falciparum malaria, a retrospective analysis. PLoS One. 2014;9:e87020.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Hanson J, Lee SJ, Mohanty S, Faiz MA, Anstey NM, Charunwatthana P, et al. A simple score to predict the outcome of severe malaria in adults. Clin Infect Dis. 2010;50:679–85.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Kaung M, Kyi TT, Aung NM, Kyaw MP, Min M, Htet ZW, et al. The prognostic utility of bedside assessment of adults hospitalised with malaria in Myanmar: a retrospective analysis. Malar J. 2015;14:63.View ArticlePubMedPubMed CentralGoogle Scholar
  23. World Health Organization. WHO guidelines for the treatment of malaria 2010. Geneva: World Health Organization; 2010.Google Scholar
  24. World Health Organization. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2006.Google Scholar
  25. Dondorp AM, Desakorn V, Pongtavornpinyo W, Sahassananda D, Silamut K, Chotivanich K, et al. Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med. 2005;2:e204.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, Piera K, et al. Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci U S A. 2008;105:17097–102.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Erhart LM, Yingyuen K, Chuanak N, Buathong N, Laoboonchai A, Miller RS, et al. Hematologic and clinical indices of malaria in a semi-immune population of western Thailand. Am J Trop Med Hyg. 2004;70:8–14.PubMedGoogle Scholar
  28. Tagny CT, Mbanya D, Tapko JB, Lefrere JJ. Blood safety in Sub-Saharan Africa: a multi-factorial problem. Transfusion. 2008;48:1256–61.View ArticlePubMedGoogle Scholar
  29. Looareesuwan S, Davis JG, Allen DL, Lee SH, Bunnag D, White NJ. Thrombocytopenia in malaria. Southeast Asian J Trop Med Public Health. 1992;23:44–50.PubMedGoogle Scholar
  30. Severe malaria. Trop Med Int Health. 2014, 19:7–131.Google Scholar
  31. Chotivanich K, Sritabal J, Udomsangpetch R, Newton P, Stepniewska KA, Ruangveerayuth R, et al. Platelet-induced autoagglutination of Plasmodium falciparum-infected red blood cells and disease severity in Thailand. J Infect Dis. 2004;189:1052–5.View ArticlePubMedGoogle Scholar
  32. Wassmer SC, Lepolard C, Traore B, Pouvelle B, Gysin J, Grau GE. Platelets reorient Plasmodium falciparum-infected erythrocyte cytoadhesion to activated endothelial cells. J Infect Dis. 2004;189:180–9.View ArticlePubMedGoogle Scholar
  33. MacPherson GG, Warrell MJ, White NJ, Looareesuwan S, Warrell DA. Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am J Pathol. 1985;119:385–401.PubMedPubMed CentralGoogle Scholar
  34. Turner GD, Morrison H, Jones M, Davis TM, Looareesuwan S, Buley ID, et al. An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol. 1994;145:1057–69.PubMedPubMed CentralGoogle Scholar
  35. Lacerda MV, Fragoso SC, Alecrim MG, Alexandre MA, Magalhaes BM, Siqueira AM, et al. Postmortem characterization of patients with clinical diagnosis of Plasmodium vivax malaria: to what extent does this parasite kill? Clin Infect Dis. 2012;55:e67–74.View ArticlePubMedGoogle Scholar
  36. Leal-Santos FA, Silva SB, Crepaldi NP, Nery AF, Martin TO, Alves-Junior ER, et al. Altered platelet indices as potential markers of severe and complicated malaria caused by Plasmodium vivax: a cross-sectional descriptive study. Malar J. 2013;12:462.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Yeo TW, Lampah DA, Tjitra E, Piera K, Gitawati R, Kenangalem E, et al. Greater endothelial activation, Weibel-Palade body release and host inflammatory response to Plasmodium vivax, compared with Plasmodium falciparum: a prospective study in Papua. Indonesia J Infect Dis. 2010;202:109–12.View ArticlePubMedGoogle Scholar
  38. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395–424.View ArticlePubMedGoogle Scholar
  39. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987;2:1057–8.View ArticlePubMedGoogle Scholar
  40. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007;7:803–15.View ArticlePubMedGoogle Scholar
  41. Dondorp AM, Lee SJ, Faiz MA, Mishra S, Price R, Tjitra E, et al. The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis. 2008;47:151–7.View ArticlePubMedGoogle Scholar
  42. McKenzie FE, Prudhomme WA, Magill AJ, Forney JR, Permpanich B, Lucas C, et al. White blood cell counts and malaria. J Infect Dis. 2005;192:323–30.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Warrell DA, Looareesuwan S, Warrell MJ, Kasemsarn P, Intaraprasert R, Bunnag D, et al. Dexamethasone proves deleterious in cerebral malaria. A double-blind trial in 100 comatose patients. N Engl J Med. 1982;306:313–9.View ArticlePubMedGoogle Scholar

Copyright

© Hanson et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement